Pds biotech reports median overall survival (os) of 21 months in advanced, refractory cancer patients having few remaining treatment options and with reported historical survival of 3-4 months

Median os of 21 months in 29 checkpoint inhibitor (cpi) refractory hpv16-positive cancer patients in national cancer institute-led phase 2 clinical trial of pds0101 triple combination median os of 21 months in 29 checkpoint inhibitor (cpi) refractory hpv16-positive cancer patients in national cancer institute-led phase 2 clinical trial of pds0101 triple combination
PDSB Ratings Summary
PDSB Quant Ranking